PAVmed (FRA:1P5) Moat Score: 3/10 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1P5 PAVmed Inc FRA:1P5
35 GF Score
Price €4.13
GF Value €0.93
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is PAVmed Moat Score?

PAVmed FRA:1P5 -2.25% 35 Moat Score is 3 as of Aug. 04, 2026. GuruFocus rates FRA:1P5 with a GF Score™ of 35/100 and a GF Value™ of €0.93 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 839 Medical Devices & Instruments companies, PAVmed ranks better than 75.69% on this metric.

PAVmed has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

PAVmed has No Moat: PAVmed has some potential in medical device innovation, but lacks market leadership, strong brand strength, and significant customer switching costs. The competitive nature of the industry limits its moat to a very weak level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PAVmed might have No Moat - Very weak/transient advantages.

PAVmed  (FRA:1P5) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PAVmed Moat Score Related Terms

FRA:1P5 vs BDMD, NSPR, TELA: Moat Score Comparison

For the Medical Devices subindustry, PAVmed's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PAVmed Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's Moat Score distribution charts can be found below:

* The bar in red indicates where PAVmed's Moat Score falls into.


FRA:1P5
35GF Score
PAVmed Inc FRA:1P5
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
PAVmed (FRA:1P5) has a Moat Score of 3 as of Aug. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PAVmed ranks #204 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 24.3%.
Is PAVmed's Moat Score too high?
PAVmed's current Moat Score is 3. Based on the distribution chart, PAVmed ranks #204 out of 839 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PAVmed has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PAVmed's Moat Score compare to BDMD and NSPR?
According to the Medical Devices & Instruments industry distribution chart, PAVmed ranks #204 out of 839 companies for Moat Score. This places PAVmed in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. PAVmed's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PAVmed stock overvalued right now?
Based on GuruFocus' analysis, PAVmed (FRA:1P5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.93, compared to a current price of €4.13 — trading 343.5% above its estimated fair value. The current Moat Score is 3. PAVmed's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PAVmed (FRA:1P5), the current Moat Score is 3 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PAVmed (FRA:1P5) Overvalued in 2026?

Based on GuruFocus' analysis, PAVmed stock appears to be overvalued. The current stock price of €4.13 is trading 343.5% above its estimated GF Value™ of €0.93. GuruFocus considers PAVmed to be Significantly Overvalued.

Key valuation signals for FRA:1P5:

  • Moat Score: 3
  • GF Value™: €0.93 vs. price of €4.13 (343.5% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the FRA:1P5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PAVmed Business Description

Other Exchanges PAVM:USA
Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
35GF Score

Get the complete analysis for FRA:1P5

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.13
Price
€0.93
GF Value